Nav: Home

Novel compound interrupts malaria parasite's lifecycle

October 07, 2019

An international group of researchers has proven that a molecule called TCMDC-135051 can selectively inhibit a protein that is essential to the lifecycle of Plasmodium falciparum, one of the parasites that causes malaria.

The results of the study, just published in the journal Science, pave the way for the development of a new antimalarial drug. Malaria kills nearly 500,000 people per year, and more than 200 million new cases of the disease are reported annually. One of the obstacles to eradication is the parasite's emerging resistance to existing drugs.

The authors of the journal article include members of the University of Campinas's Center for Medicinal Chemistry (CQMED-UNICAMP) in São Paulo State. CQMED is a unit of the Brazilian Agency for Industrial Research and Innovation (EMBRAPII) that specializes in biopharmaceuticals and pharmaceuticals. It is headed by Professor Paulo Arruda and supported by São Paulo Research Foundation - (FAPESP) through the foundation's Research Partnership for Technological Innovation (PITE).

CQMED also belongs to the Structural Genomics Consortium (SGC), an international network that works to accelerate drug discovery through open-access research by scientists at universities, pharmaceutical companies and nonprofit organizations.

The article shows that the molecule TCMDC-135051, which is synthesized by global pharmaceutical giant GSK, acts specifically on P. falciparum's cyclin-dependent-like protein kinase PfCLK3 without affecting human proteins.

"Inhibition of PfCLK3 affects the parasite in both the asexual stage of its development, when it proliferates in human cells and causes symptoms, and the sexual stage, when it can be transmitted back to the vector insect, repeating the cycle by infecting other humans," said Paulo Godoi, who conducted the research during a postdoctoral fellowship with CQMED.

Dev Sriranganadane, currently on a postdoctoral internship at CQMED, also took part in the study. The research was led by Andrew Tobin, Professor of Molecular Pharmacology at the University of Glasgow in the UK.

"The UNICAMP group played a key role in this project. They were able to say whether our drug might have other effects in addition to inhibiting PfCLK3. Without that information we couldn't have proceeded with the study," Tobin told.

Because parasites of the genus Plasmodium are becoming increasingly resistant to existing antimalarials, novel compounds with the potential to be developed into drugs that prevent transmission and may even cure the disease are urgently needed.

"This PfCLK3 inhibitor is highly promising, as it can eliminate the parasite in all stages of its lifecycle," Godoi said.

PfCLK3 controls the activity and production of other proteins required by the parasite to stay alive. By blocking these, TCMDC-135051 kills P. falciparum and not only prevents transmission but can also treat the disease in humans.

In a high-throughput screening assay to identify selective PfCLK3 inhibitors, the researchers analyzed 24,619 compounds and selected TCMDC-135051 because it showed the highest selectivity and potency in this regard.

The study also suggests that this molecule is effective against other species of Plasmodium. According to Godoi, in vitro trials showed activity against CLK3 in cultured cells of P. viva, P. knowlesi and P. berghei.

"We also tested it in mice infected with P. berghei. The results of this in vivo trial showed that the parasite was eliminated from the bloodstream after five days of infection," he said.

Brazilian contribution

To be considered safe, molecules that are drug candidates must not interfere with human proteins. Parasites of the genus Plasmodium and humans have protein kinases, which orchestrate the activity of almost all cellular processes. The human kinase that most closely resembles Plasmodium's PfCLK3 is PRPF4B. Tobin asked CQMED to confirm that TCMDC-135051 was safe because its members are among the few scientists who study the functions of PRPF4B.

"We had PRPF4B interact with the new molecule at different concentrations, and it proved unable to inhibit the human kinase even at the highest concentration," Godoi said.

To guarantee the molecule's safety so that drug development could proceed, the researchers had to show that it did not affect the activity of the proteins required by humans. "We focused on a protein that's rarely been studied. The outcome was positive because it enabled this new study, which demonstrated major potential for the development of a new drug," said Rafael Couñago, CQMED's scientific coordinator.

To become a drug, however, this inhibitor will have to be submitted to more tests. "We need to improve the molecule's safety even more. Then, it will be ready for trials in humans. That stage will take between three and five years," Tobin said.
-end-
About São Paulo Research Foundation (FAPESP)

The São Paulo Research Foundation (FAPESP) is a public institution with the mission of supporting scientific research in all fields of knowledge by awarding scholarships, fellowships and grants to investigators linked with higher education and research institutions in the State of São Paulo, Brazil. FAPESP is aware that the very best research can only be done by working with the best researchers internationally. Therefore, it has established partnerships with funding agencies, higher education, private companies, and research organizations in other countries known for the quality of their research and has been encouraging scientists funded by its grants to further develop their international collaboration. You can learn more about FAPESP at http://www.fapesp.br/en and visit FAPESP news agency at http://www.agencia.fapesp.br/en to keep updated with the latest scientific breakthroughs FAPESP helps achieve through its many programs, awards and research centers. You may also subscribe to FAPESP news agency at http://agencia.fapesp.br/subscribe.

Fundação de Amparo à Pesquisa do Estado de São Paulo

Related Protein Articles:

Substituting the next-best protein
Children born with Duchenne muscular dystrophy have a mutation in the X-chromosome gene that would normally code for dystrophin, a protein that provides structural integrity to skeletal muscles.
A direct protein-to-protein binding couples cell survival to cell proliferation
The regulators of apoptosis watch over cell replication and the decision to enter the cell cycle.
A protein that controls inflammation
A study by the research team of Prof. Geert van Loo (VIB-UGent Center for Inflammation Research) has unraveled a critical molecular mechanism behind autoimmune and inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis.
Resurrecting ancient protein partners reveals origin of protein regulation
After reconstructing the ancient forms of two cellular proteins, scientists discovered the earliest known instance of a complex form of protein regulation.
Sensing protein wellbeing
The folding state of the proteins in live cells often reflect the cell's general health.
Protein injections in medicine
One day, medical compounds could be introduced into cells with the help of bacterial toxins.
Discovery of an unusual protein
Scientists from Bremen discover an unusual protein playing a significant role in the Earth's nitrogen cycle.
Protein aggregation: Protein assemblies relevant not only for neurodegenerative disease
Amyloid fibrils play a crucial role in neurodegenerative illnesses. Scientists from Heinrich Heine University Düsseldorf (HHU) and Forschungszentrum Jülich have now been able to use cryo-electron microscopy (cryo-EM) to decode the spatial structure of the fibrils that are formed from PI3K SH3 domains - an important model system for research.
Old protein, new tricks: UMD connects a protein to antibody immunity for the first time
How can a protein be a major contributor in the development of birth defects, and also hold the potential to provide symptom relief from autoimmune diseases like lupus?
Infection-fighting protein also senses protein misfolding in non-infected cells
Researchers at the University of Toronto have uncovered an immune mechanism by which host cells combat bacterial infection, and at the same time found that a protein crucial to that process can sense and respond to misfolded proteins in all mammalian cells.
More Protein News and Protein Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Processing The Pandemic
Between the pandemic and America's reckoning with racism and police brutality, many of us are anxious, angry, and depressed. This hour, TED Fellow and writer Laurel Braitman helps us process it all.
Now Playing: Science for the People

#568 Poker Face Psychology
Anyone who's seen pop culture depictions of poker might think statistics and math is the only way to get ahead. But no, there's psychology too. Author Maria Konnikova took her Ph.D. in psychology to the poker table, and turned out to be good. So good, she went pro in poker, and learned all about her own biases on the way. We're talking about her new book "The Biggest Bluff: How I Learned to Pay Attention, Master Myself, and Win".
Now Playing: Radiolab

Invisible Allies
As scientists have been scrambling to find new and better ways to treat covid-19, they've come across some unexpected allies. Invisible and primordial, these protectors have been with us all along. And they just might help us to better weather this viral storm. To kick things off, we travel through time from a homeless shelter to a military hospital, pondering the pandemic-fighting power of the sun. And then, we dive deep into the periodic table to look at how a simple element might actually be a microbe's biggest foe. This episode was reported by Simon Adler and Molly Webster, and produced by Annie McEwen and Pat Walters. Support Radiolab today at Radiolab.org/donate.